Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
== Notable people == Eric Decker, National Football League player Alvin Ganzer (1911–2009), film director, born in Cold Spring John J. Kinzer (1891–1986), Minnesota state legislator and farmer Doug Stang, Minnesota state legislator Justin Stommes, professional basketball player; graduated from Rocori High School
==== Alkene and tetrazole photoclick reaction ==== The tetrazole-alkene "photoclick" reaction is another dipolar addition that Huisgen first introduced in the late 1960s (ChemBioChem 2007, 8, 1504. (68) Clovis, J. S.; Eckell, A.; Huisgen, R.; Sustmann, R. Chem. Ber. 1967, 100, 60). Tetrazoles with amino or styryl groups that may be activated by UV light at 365 nm react quickly, so that the UV light does not have to be on for a long time (usually approximately 1–4 minutes) to make fluorogenic pyrazoline products. This reaction scheme is well suited for the purpose of labeling in live cells, because UV light at 365 nm damages cells minimally. Quantum yields for short wavelength UV light may be higher than 0.5, allowing tetrazoles to be used selectively in combination with another photoligation reactions, where at the short wavelength the tetrazole ligation reaction proceeds nearly exclusively and at longer wavelength other reactions (e.g. ligation via o-quinodimethanes) proceeds preferably. Finally, the non-fluorogenic reactants give rise to a fluorogenic product, equipping the reaction with a built-in spectrometric handle. Both tetrazoles and the alkene groups have been incorporated as protein handles as unnatural amino acids, but this benefit is not unique. Instead, the photoinducibility of the reaction makes it a prime candidate for spatiotemporal specificity in living systems. Challenges include the presence of endogenous alkenes, although usually cis (as in fatty acids) they can still react with the activated tetrazole.
The show also included a behind-the-scenes tour of the In-N-Out Headquarters. Gift items are sold at an In-N-Out "Company Store" near the chain's birthplace in Baldwin Park, California. A replica of the first store from 1948 was unveiled near the original site in 2014.
== SJ == SJ (s) Svalbard and Jan Mayen (ISO 3166 digram) (i) Societas Iesu (Latin: The Society of Jesus, the Jesuit order) (i) Statens Järnvägar (Swedish State Railways) SJA – (i) Staff Judge Advocate (military law) SJC – (i) Supreme Judicial Court of Massachusetts (note: the highest court in the state of Maine is also called the Supreme Judicial Court) SJM – (s) Svalbard and Jan Mayen (ISO 3166 trigram) SJW – (i) Social Justice Warrior
James Upton (1670 in Wilmslow–1749), an English clergyman, schoolmaster and literary editor. Samuel Finney (1719 in Wilmslow–1798), an English miniature painter. William Ewart Gladstone (1809–1898), politician, statesman and Prime Minister four separate times, lived at the Wilmslow Rectory between January and April 1828 to study under the supervision of Reverend John Turner James Tait (1863–1944 in Wilmslow), medieval historian, noted for his retiring, scholarly life in Wilmslow Sir Thomas Barnes (1888–1964), lawyer and HM Procurator General and Treasury Solicitor 1934–1953 Helen Tolson (1888–1955), suffragette, active in the Women's Social and Political Union Alan Turing (1912–1954 in Wilmslow), computer science pioneer and driving force behind the Bombe machine for cracking the German Enigma cypher, is perhaps Wilmslow's most notable resident; he died locally In 2004, a blue plaque was placed on his house in his honour Patrick George (1923 in Wilmslow–2016), an English painter who taught at the Slade School of Fine Art Roger Thatcher (1926–2010), a British statistician, spent his formative early years in Wilmslow Antony Grey (1927 in Wilmslow–2010), pioneer gay rights activist Ronald Brunskill (1929–2015), architectural historian Rod Davies (1930–2015), astronomer and cosmologist, president of the Royal Astronomical Society, and director of Jodrell Bank Observatory Peter Emerson Jones (born 1935), owner of the Emerson Group, a property business lives locally Richard Evans (born 1945 in Wilmslow), a graphic designer, photographer and illustrator Iqbal Ahmed (born 1956), the owner and CEO of the Seamark Group's Asian food business, based in Manchester, lives in Wilmslow John Harris (born 1969 in Wilmslow), a British journalist, writer and critic.
Sources: en.wikipedia.org
The United States Department of Defense asks the US defense sector to accelerate the manufacturing and delivery of armaments, including ammunition that is in short supply because of the 2026 Iran war. Royce White becomes the second former NBA player, after Enes Kanter Freedom, to declare that they are eligible for the 2027 WNBA draft. August 9 – 2026 cyclosporiasis outbreak, salmonellosis in the United States: Taylor Farms extends its recalls to products containing jalapeños after they were linked to the ongoing salmonellosis outbreak in the United States. Taylor Farms currently has a recall for iceberg lettuce linked to cyclosporiasis. August 10 Staff secretary Will Scharf is named as White House counsel by Trump. Trump states that he instructed US negotiators to demand reparations from the Iranian regime for Americans it has killed and seriously injured in conflicts, as well as the families of protesters who were slain in Iran, falsely claiming that it was involved in the attack on the USS Cole. Trump also states that the regime should be held accountable for damages and deaths inflicted on Lebanese, Palestinian, Syrian, and Yemeni civilians. August 11 Democratic senators Richard Blumenthal and Adam Schiff investigate the alleged coordination between ICE and the Iranian regime to deport detainees. US rights organizations sue Trump over sanctions against the ICC. August 12 A Pentagon assessment finds that US strikes targeting the Houthis killed 153 civilians in Yemen over the past year.
Chondrocytes can be prepared by sequential enzymatic digestion of cartilage with Pronase and Collagenase and cultured in DMEM-F12 cell culture media. Transplantation of dedifferentiated chondrocytes often leads to the formation of fibrous tissue formation. Redifferentiation of dedifferentiated chondrocytes in the 3-D system (spheroid culture) restore morphological and functional properties. Carticel is a procedure for restoring articular knee cartilage with autologous chondrocyte implantation; it was the first cell therapy to be approved by the U.S. Food and Drug Administration, under accelerated approval in 1997. In Australia, Ortho-ACI, a suspension of cultured autologous chondrocytes, is indicated for use in the treatment of cartilage lesions associated with the knee, patella, and ankle. Chondronectin Endochondral ossification Intramembranous ossification List of human cell types derived from the germ layers List of distinct cell types in the adult human body Histology image: 03317loa – Histology Learning System at Boston University Stem cell information
The function of intrinsic termination is to signal for the dissociation of the ternary elongation complex (TEC), which ends transcription and releases RNA polymerase and its associated cofactors as well as the new RNA transcript. Intrinsic termination occurs independently of the protein Rho, in contrast to Rho-dependent termination, where the Rho protein must act on the RNA polymerase in order for it to dissociate from the transcription complex. Here, there is no extra protein and the transcript forms its own loop structure. Intrinsic termination thus regulates the level of transcription as well, determining how many polymerases can transcribe a gene over a given period of time, and can help prevent interactions with neighboring chromosomes.
=== 2016 Helsinki, Finland === On 3 and 4 March 2016, unusually high levels of caesium-137 were detected in the air in Helsinki, Finland. According to Finland's Radiation and Nuclear Safety Authority (STUK), measurements showed 4000 μBq/m3—approximately 1,000 times the usual background level. A STUK investigation traced the source to a building from which STUK itself and a radioactive waste treatment company operate.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.